Physiological Saline Market size is anticipated to increase exponentially from 2022 to 2028, given the significant uses of saline physiological solutions in medicine, including the cleaning of wounds, clearing sinuses, and treating dehydration. In addition, the escalating rate of surgical procedures will further augment the industry expansion during the forecast timeframe, as physiological normal saline is the most utilized intravenous solution. Physiological saline refers to a solution of salts that is essentially isotonic with blood or tissue fluids. These normal saline solutions, especially the sterile with the concentration of normal salt, are commonly used in medicine and are prepared by dissolving 9 grams of salt per liter.
Rising incidence of sepsis is one of the prominent trends characterizing overall physiological saline market dynamics through 2028. According to the CDC, nearly 1.7 million adults in the United States develop sepsis and around 270,000 die as a result per year. Situations such as these will proliferate the need for the product, as it is often deployed as a preferred resuscitation fluid for patients with septic shock. Furthermore, the global burden of breast cancer is also expected to contribute to the market growth, given the emergence of chemotherapy infusion or intravenous (IV) infusion as a common treatment for this type of chronic disease.
Based on product type, the plastic bottle segment will account for a considerable share in the physiological saline market by 2028. This can be credited to the mounting adoption of high-density polyethylene in the production of plastic IV and saline bottles, owing to its cost-effectiveness, impact resistance, adequate moisture protection, and other favorable attributes. However, the adverse impacts of IV bottles made of polypropylene plastics, such as the high susceptibility to microbial attack and flammability, may hinder segmental expansion to a certain extent in the coming years.
North America physiological saline market is set to depict a strong growth rate through 2028, driven by the growing prevalence of chronic diseases such as diabetes in the region. As per the American Diabetes Association’s data, the number of Americans diagnosed with diabetes is likely to surge from 11 million in 2000 to 29 million in 2050. This factor may proliferate the regional industry forecast, as physiological sodium chloride solution is a commonly used IV fluid in treating diabetic ketoacidosis. Moreover, the escalating number of people with chronic wounds such as foot ulcers will further foster the demand for physiological salt solutions across the region.
Some of the key players in the market include Cisen, SSY Group (formerly Lijun International Pharmaceutical (Holding) Co., Ltd.), CR Double-Crane, Kelun Group, Otsuka, B. Braun, Fresenius Kabi, Hospira (Pfizer), and Baxter. These firms are implementing strategies such as new product launches, mergers, and acquisitions to strengthen their presence and expand their business footprint across the global market.
The novel coronavirus pandemic posed negative impacts on the wound care sector, due to the disruptions in the diagnostic workup, access to primary care physicians, and hospitalization during the peak of the crisis. Multiple patients with chronic leg ulcers, for example, have had restricted access to care services during the pandemic, owing to the overburdened healthcare systems. Despite these COVID-19-induced disruptions, the emergent need for rapid IV fluid delivery for COVID-19 patients experiencing secondary systemic sepsis may contribute to the industry expansion over the coming years.
Market, By Product Type
Market, By End-users
The above information is provided for the following regions and countries: